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Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main
columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side eﬀects
and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of
therapeutic strategies which are as eﬀective as standard therapies but permit the patients a life without severe negative side eﬀects.
Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may
provide a venue to achieve this goal. Using the patient’s own immune system by activation of humoral and cellular immune
responses to target the cancer cells has shown ﬁrst promising results in clinical trials and may allow reduced toxicity standard
therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early
clinical results to an eﬀective treatment of patients.
1.Introduction
1.1. Immunotherapy and Cancer. Canceris a leading cause of
deathandisresponsibleforamagnitudeofalldisease-related
deaths worldwide [1, 2]. Standard cancer therapy includes
intensive chemo- and/or radiotherapy able to eﬀectively
eradicate cancer cells but with the disadvantage of severe
side eﬀects. Additionally, many cancers are diagnosed at
an advanced tumor stage, where standard therapy has its
limitations and is only able to cure low numbers of patients.
Vaccination against canceris a promising approach toinduce
the immune system to speciﬁcally target the tumor cells.
However, the successful use of cancer vaccines is
dependent on several problems that need to be overcome.
Advanced tumor progression often leads to immune sup-
pression; patients are weakened by previous therapies and
aging [3]. In mouse tumor models, there are indications
that young mice are better protected against a lethal tumor
challenge showing improved primary immune responses
than older mice making the use of vaccines in patients
at an advanced age challenging because the thymus stops
producing na¨ ıve T cells with age [4, 5].
The fact that the status of the patient’s immune system
is critical for the ability to develop an eﬀective antitu-
mor immune response is supported by the correlation
between the amount of tumor-inﬁltrating lymphocytes with
a favourable prognosis [6, 7]. In contrast, patients who are
chronically immune suppressed as a result of therapy or
other reasons have an unfavourable prognosis [8, 9].
The challenge is to amplify the patients’ own immune
response and translate it into a long-lasting memory without
induction of unmanageable autoimmunity in order to
protect against metastasis in the future.
One approach is the use of whole inactivated tumor cells
as a source of antigen based on promising results in mouse
models [10]. The biological background to this strategy is2 Clinical and Developmental Immunology
the presence of tumor-speciﬁc or tumor-associated antigens
expressed by the cells used for vaccination and the malignant
target cells. Many antigens involved in eﬀective cell-based
vaccination strategies were identiﬁed, characterized, and
found to be also expressed on normal cells. The expression is
often compartmentalized in distinct tissues and is frequently
of a signiﬁcantly lower magnitude than on the cancer cells;
however, this fact always bears a risk of autoimmunity.
Therefore, the ideal cancer vaccine targets tumor-speciﬁc
antigens expressed exclusively on tumor cells or tumor-
associated antigens without harming normal cells expressing
the same antigen, a problem which is hard to solve. An
important key to success of cancer vaccines is to break self-
tolerance, since tumor-associated antigens are self-antigens
overexpressed by tumor cells. This challenge involves the use
ofdistinctprime-boost strategieswith diﬀerentformulations
of the tumor-associated antigen used for vaccination. This
includes peptide- or protein-based antigens or delivery with
viral vectors, which need to be used in combination in order
to elicit measurable immune responses [11, 12]. Promising
results were obtained with the use of self-replicating RNA
and DNAvaccines which were able tobreaktoleranceagainst
tumor-associated self-antigens involving pathways of innate
a n t i v i r a li m m u n i t y .T h e s ev a ccines enhance the immuno-
genicity and production of antigen-speciﬁc antibodies and
CD8+ T cells without negative side eﬀects. Although the
production of antigen was not increased in comparison with
conventional DNA vaccines, it is likely that the eﬃcacy of
the self-replicating vaccines was associated with caspase-
dependent apoptotic cell death of transfected cells and a
subsequent uptake of these cells by dendritic cells (DCs)
[13–15].
Application of xenogeneic tumor-associated antigens
is another interesting strategy to overcome some of the
obstacles mentioned above. The magnitude of an antitumor
response is clearly improved by using a tumor-associated
antigen obtained from a diﬀerent species sharing critical
epitopes ﬂanked by xenogeneic protein sequences further
stimulating the antitumor response [16–19]. The delivery
of such xenogeneic tumor-associated antigens by DNA
vaccination may be a promising venue to the design of a
successful strategy.
1.2. DNA Vaccination. Historical observations that transfer
of foreign DNA by diﬀerent in vitro and in vivo techniques
led to expression of antigen were the basis for the generation
of DNA vaccines [20]. DNA vaccines can consist of tumor-
speciﬁc or tumor-associated antigens (TAAs) and additional
immune-stimulatory factors cloned into a bacterial plasmid
downstream of an appropriate eukaryotic promoter for
strong and stable expression.
TAAs used for cancer vaccines are exogenous viral anti-
gens expressed by virus-induced cancers, tumor-restricted
antigens also called neoantigens, tumor-associated diﬀeren-
tiation antigens that are only expressed in speciﬁc tissues, or
generally expressed antigens that are overexpressed in cancer
cells.
Cancer vaccines include MHC class I and class II
epitopes, multiple TAAs to eﬀectively target the whole
inhomogeneous tumor population to decrease the risk of
immune escape, and can contain TAAs that correspond
to proteins involved in tumor transformation [21]. DNA
minigenes are a special type of DNA vaccines harbouring
only short antigen epitopes which can eﬃciently induce a
cytotoxic T cell (CTL), B-cell or T-helper cell response. They
are as eﬀective as whole cDNA vaccines but without the risk
of introducing a functional cDNA with possible devastating
consequences [22–25]. This is especially important if anti-
gens that are used can function as oncogenes. If whole cDNA
vaccines are favoured, rearranged or mutated sequences
were shown to be useful for full immunological activity
without the risk of negative properties of the functional
protein [26, 27]. DNA vaccines have many advantages if
compared with classical vaccines; they combine the diversity
of possible TAAs expressed on whole tumor cells or subunit
vaccines with the eﬃciency of in vivo antigen synthesis and
presentation able to induce both cellular (CD4+ and CD8+
cells) and humoral immune responses [28].
The risks of DNA vaccines are limited [29]. Several
groups demonstrated that cancer vaccines can be eﬀective
in induction of speciﬁc immunity against cancer-associated
antigens without negative side eﬀectslikeintegration of plas-
mid DNA into the host genomes or induction of pathogenic
anti-DNA antibodies [30–38]. The results in animal models
and initial clinical trials are promising but so far have
not resulted in a successful, standardized translation into
the clinic, emphasizing the enormous diﬀerences between
animal models and patients. Possible reasons may be related
to the compromised immune system of the cancer patients
after theirchemo- and/orradiotherapy. Additionally, tumors
develop mechanisms to escape the immune system, such as
the loss of MHC class I molecules or antigen, so they cannot
be recognized by CTLs [39–42]. Other mechanisms are the
occurrence of regulatory T cells that negatively inﬂuence
the induction of anti-tumour responses, systemic defects in
immune cells, secretion of immunosuppressive cytokines,
resistance to apoptosis, and many more [43, 44], which need
to be addressed.
1.3. Eﬀective Activation of the Patient’s Immune System
by DNA Vaccines. DNA vaccines capable to activate the
patient’s immune system to eﬀectively target cancer need
the activation of eﬀector cells that are able to kill the
t u m o ro rc a ni n d i r e c t l yt r i g g e rac a s c a d et h a ts u b s e q u e n t l y
lead to its eradication. Na¨ ıve T cells are a basic part of
this complex system which are activated if they get two
independent signals. The ﬁrst signal is provided by binding
of a speciﬁc antigen-MHC class I complex to its T cell
receptor (TCR). The second costimulatory signal is diverse
in nature and may consist of CD40 expressed on antigen-
presenting cells (APCs) or soluble factors such as cytokines
(IL-2). To increase the immunogenicity of tumor cells, they
were manipulated toexpress costimulatorymoleculesand/or
cytokinestherebysigniﬁcantlyenhancing theinductionofan
immune response [45, 46].Clinical and Developmental Immunology 3
Thedeliverysystemusedfortheapplicationofanticancer
vaccines also plays an important role in increasing the
amplitudeof an immune response. Plasmid-based DNAvac-
cines can be applied with ballistic delivery (gene gun) [47],
liposomal or microsphere encapsulation [48]i n c o r p o r a t e d
inbacterialorhostcellcarriers[49,50],orbyelectroporation
[51–54]. The latter technique is used eﬃciently in preclinical
and clinical trials of melanoma and prostate cancer. Using
bacteria as DNA vaccine vehicles bears the advantage of
eﬃcient stimulation of the innate immune system through
the recognition of lipopolysaccharides (LPSs) in the bacteria
outer membrane. LPSs stimulate APCs by binding to Toll-
like receptor 4 (TLR4) which subsequently supports an
eﬃcient activation of T cells, directly activates natural
killer cells (NK cells), or leads to an increased lifetime of
antigen-speciﬁc T cells [12, 55]. Unmethylated CpG motifs
included in DNA of bacterial origin have an additional
immune stimulatory eﬀect on cells of the innate immune
system. Binding of CpGs to Toll-like receptor 9 (TLR9)
expressed on DCs, NK cells, or monocytes/macrophages
leads to further maturation and activation of these cells and
subsequent secretion of proinﬂammatory cytokines of the
Th 1type includingIL-12, TNF-α,I F N- α,andIFN-γ and the
upregulation of costimulatory molecules such as CD80 and
CD86 onAPCs [56–58]. The dependency of TLR9 activation
by CpGs is challenged by recent observations indicating that
the DNA sugar backbone is also crucial for either activation
or inhibition of TLRs by DNA. Natural DNA activates TLRs
with phosphodiester (PD) backbone independent of CpGs
in contrast to synthetic phosphorothioate- (PS-) modiﬁed
DNA, which is TLR antagonistic. In the latter case, CpG
motifs can transform the antagonistic PS-modiﬁed DNA
to a strong activator of TLRs restricting the dependency
of CpGs on TLR activation to this special case [59, 60].
Furthermore, the detection of foreign non-CpG DNA is
also mediated by TLR-independent sensors leading to the
expression of interferon genes and induction of innate
immunity. One candidate sensor called DNA-dependent
activator of interferon regulatory factors (DAI)was shown to
directly interact with DNA in interplay with the interferon
regulatory factor 3 transcription factor (IRF3) leading to
a release of interferon-β in a TANK-binding kinase 1-
(TBK1-) dependent manner [61–63]. Another crucial factor
in the activation of the TBK1 pathway seems to be STING
(stimulatorofinterferongenes)[64].Thisnovelindependent
pathwayshows thatAT-rich DNAcanalso serveasa template
for RNA polymerase III leading to a transcription into
double-stranded RNA (dsRNA). dsRNA subsequently acts
as a ligand for the potential cytosolic DNA sensor RIG-I
(Retinoic acid-induced gene I) and to a production of type
I interferons [65, 66].
1.4. Presentation of Antigens Encoded in DNA Vaccines.
Based on the DNA vaccine delivery system and the DNA
design of the antigen sequences, there are at least three
diﬀerent mechanisms as DNA vaccines can be processed
and presented in vivo. First, DNA vaccines can directly
lead to production of the antigen by somatic cells like
keratinocytesormyocytes. These cells share a poorcapability
to directly present processed antigen to immune cells by
MHC class I and II molecules. Therefore, this mechanism
is considered to play only a subordinate role. Second, the
production of antigen by somatic cells may result in eﬀective
presentation to the immune system by a mechanism called
“cross-priming”. Antigen may be released from the site of
production travelling to the draining lymph node, where
i ti st a k e nu pb yA P C sp r o c e s s e da n dp r e s e n t e dt oTc e l l s
[67, 68]. Third, DNA vaccines also lead to the production
and direct presentation of antigen by professional APCs. For
this purpose, the normal infection pathway of intracellular
bacteria, for example, attenuated Salmonella thyphimurium,
can be used for oral DNA vaccination. The bacteria enter
the host through the gastrointestinal tract after oral gavage
and move through the M cells that cover the Peyer’s patches
(lymph nodes) of the gut. From there, they enter APCs
like macrophages or DCs by phagocytosis. In the APCs, the
bacteria die, delivering multiple copies of the vaccine DNA
that can encode for antigen to the phagosome or cytosol
[69, 70].
1.5. Processing DNA-Encoded Antigen. The activation of
CTLs which are keyplayers in DNAvaccine-mediated tumor
immunity is induced by degradation of protein components
into smaller peptides and presentation of antigen by APCs
[71, 72].
Processedantigenscanbeeitherpresentedbytheendoge-
nous or the exogenous pathway. CD8+ T cells, the precursors
of CTLs, are in general activated by intracellular pathogen-
derived antigens of 8–10 amino acids length which are
presented by MHC class I molecules (endogenous pathway)
[73, 74]. In contrast, CD4+ T-helper cells generally recognize
exogenous antigens presented as 12–15 amino acid long
peptides bound to MHC class II molecules. Uponactivation,
T-helper cells secrete cytokines, which is crucial for the
induction and maintenance of immunologic memory [75–
78]. If antigens are transported to the cytoplasm or proteins
are produced endogenously, they are degraded by the
proteasome into small peptide fragments. These peptides are
then transported by TAP1 and TAP2 into the endoplasmatic
reticulum (ER) and bind to a dimer consisting of an MHC
class I molecule and β2-microglobulin. MHC class I antigen
complexesarethentransported tothecellsurface,wherethey
are presented. The trimolecular complex can be recognized
by CD8+ cytotoxic T cells. This mechanism is important for
induction and activation of antigen-speciﬁc CD8+ T cells by
APCs and for the eﬀector function of CD8+ cytotoxic T cells
after trimolecular complex recognition on the tumor cell
resulting in subsequent target cell lysis [79–82]. Presentation
of antigens via the endogenous pathway dominantly leads
to activation of Th 1 cells and CTL responses, whereas the
exogenous pathway leads to the activation of Th 2 cells
and the production of antibodies [83, 84]. DNA vaccines
can increase the Th 1 immune response and the levels of
immunoglobulins by directly inducing the expression of
interferons, IL-12, IL-18, or TNF-α [85]. The activation
of the exogenous pathway is usually insuﬃcient to prevent
tumor growth in animal models of cancer but is in contrast4 Clinical and Developmental Immunology
preferable in the case of protection against extracellular
pathogens or in targeting chronic infections.
The introduction of speciﬁc sequences to the antigen
like an N-terminal ubiquitination signal can further enhance
the induced CTL response, preferentially of the Th 1 type
[86]. It is possible to increase the protection against virus
or tumor challenge by directing the antigen to speciﬁc
cell compartments like the proteasome leading to fast
degradation and presentation of antigen to MHC class I
molecules [87]. Ubiquitination of DNA minigenes probably
leads to polyubiquitination of the cleaved peptide epitopes
resulting in a more eﬀective delivery of the minigene to
the proteasome and an increase of the frequency of CTL
precursors [24].
2.Melanoma
Malignant melanoma is a neuroectodermal solid tumor
aﬀecting predominantly Caucasians. More than 160.000 new
cases were diagnosed in 2002 with an increasing incidence.
Despite favourable survival rates in the developed countries
of greater than 90% in early stages, around 40.000 deaths
were caused by melanoma in 2002. In the US alone, more
than 10.000 people will probably die of skin cancer in 2010,
and the prognosis of stage IV melanoma remains poor
(<20% 5y EFS) [1, 88]. Melanoma is a highly immunogenic
cancer and maybe the most prominent model for DNA
vaccination and the development of tumor vaccines in
general [89]. In patients, spontaneous complete melanoma
remission is occasionally detected, a phenomenon medi-
ated by endogenous CTLs and subsequent tumor rejection
[90, 91]. A variety of melanocyte diﬀerentiation antigens
were identiﬁed as tumor antigens and found to be highly
expressed in melanoma cells. Consequently, these antigens
were successfully used as targets for DNA vaccination, and
theirapplicationinhumans, dogs, andpreclinicalmodelsare
discussed in the following paragraphs [92, 93].
Based on the successful use of gp100, MART-1/Melan-
A, and tyrosinase, several clinical trials were conducted
or are still ongoing. In an initial study, patients with
metastatic melanoma were immunized with human gp100
(hgp100) expressing naked plasmids showing no clinical
or immunological responses, indicating that the delivery
system and adequate costimulation play an important role
for the success of this approach. For example, the use of
fowl poxvirus encoding for hgp100 or hgp100 peptides was
c a p a b l et ob r e a kt h es e l f - t o l e r a n c ea g a i n s tt h eg p 1 0 0t u m o r
antigen [40]. Also the use of particle-mediated epidermal
delivery (PMED) of hgp100 cDNA in combination with
costimulatory granulocyte macrophage colony-stimulating
factor (GM-CSF) into healthy skin of melanoma patients
revealed the recruitment of DCs to the vaccination sites.
Subsequently, a low but detectable antimelanoma immune
response was observed [94]. A role for GM-CSF DNA as
an adjuvant was established in a phase I/II trial using a
DNA vaccine encoding for hgp100 and tyrosinase epitopes
resulting in speciﬁc CD8+ responses in 42% of the treated
melanoma patients [95]. Another strategy eﬀectively break
tolerance against self-antigens is the use of xenogeneic
DNA vaccines. This is indicated by two recent phase I
trials using mouse gp100 (mgp100) DNA vaccines alone
or in combination with the human homologue. Melanoma
patients immunized with the xenogeneic vaccines developed
hgp100-speciﬁc and IFN-γ-secreting CD8+ T cells, and 30%
of them showed an immune response [16, 96].
MART-1 is another melanoma antigen used in clinical
DNA vaccination trials. In an early phase I study, 12 patients
with resected melanoma received MART-1 plasmids, again
without further adjuvant strategy. Immunological responses
were not detectable [97]. Similar poor results were observed
in nineteen patients with stage IV melanoma which were
treated with a plasmid encoding T cell epitopes from
MART-1 and tyrosinase by intranodal injection [98]. The
vaccination approach induced an immune response in some
of the patients but was not able to stop the progression of
the disease. This again suggested that DNA vaccines have to
be used in combination with adjuvants, cytokines, or in the
context of distinct prime/boost approaches to increase the
immune response for eﬀective treatment of melanoma.
Changing the application system from naked plasmid
to a viral delivery system may not be suﬃcient to translate
immune to clinical response demonstrated by clinical DNA
vaccination trials using tyrosinase as antigen. Tyrosinase was
used as single cDNA vaccine applied in stage II melanoma
patients by recombinant modiﬁed vaccinia virus Ankara
(MVA). There was a strong immune response against the
virus, indicated by virus-speciﬁc CD4+ and CD8+ T cells
and antibody titres, but no tyrosinase-speciﬁc T cells or
antibodies were detected [99]. In two subsequent clinical
trials, tyrosinase was delivered by vaccinia orfowlpox viruses
which were applied to patients with advanced metastatic
melanoma who also received systemic IL-2 [100].Antityrosi-
nase immunity was enhanced in some patients but without
clinical beneﬁt compared to eﬀects expected for IL-2 alone.
Numerous DNA vaccination studies in animal models
of melanoma demonstrated eﬃcacy. Particular success was
reported for xenogeneic strategies, viral delivery systems,
and the use of IL-2 as an adjuvant [101]. In mouse
models, eﬃcacy of DNA vaccines encoding for all known
melanoma-associated antigens was reportedincludinggp100
(melanocyte protein 17/Pmel-17), GRP (gastrin-releasing
peptide) [102], MAGE-1 (melanoma-associated antigen)
[103], MART-1, MUC-18/MCAM [104], TRP-1 (tyrosinase-
related protein-1/gp75), TRP-2, or tyrosinase. Also inhibitor
of apoptosis proteins (IAPs) like ML-IAP (melanoma
inhibitorofapoptosisprotein) [105]an ds urvi vin[106]w er e
used. In some approaches, less relevant antigens were used
such as melanoma cell lines stably transfected toexpress viral
antigensofhepatitisBvirusorHPV(humanpapillomavirus)
or human oncogenes like Mucin 1 (MUC-1) [107–109]. For
vaccination studies in mice, usually the melanoma cell line
B16 is used syngeneic to C57BL/6 mice leading to melanoma
growth and metastasis serving as a model for the human
disease [110, 111]. In view of the limited eﬃcacy of DNA
vaccines in clinical trials so far, these successful studies in
murine models reﬂect the diﬃculty of the transfer of results
from mice to man.Clinical and Developmental Immunology 5
However, there are important lessons to be learned from
animal models such as the important role of adjuvanticity
and prime/boost schedules. The majority of vaccination
studies in mice were done with gp100 as melanoma target
antigen, and some results will be discussed here in more
detail. In early studies, vaccination of mice by s.c. injec-
tion of plasmid encoding for hgp100 antigen alone or in
combination with GM-CSF DNA was conducted in a B16
model transfected with hgp100 DNA (B16/hgp100) [112,
113]. Protection against melanoma challenge and reduction
of established primary tumor growth was observed, and
hgp100-speciﬁc CTLs and antibodies were found. However,
immunity against mpg100 was poor. Changing the delivery
system by incorporation of the plasmid DNA expressing
hgp100 into liposomes was able to induce an mgp100
mediated protective immunity [114]. Vaccination induced a
delayed primary tumor growth, a phenomenon which was
also seen in another study using an mgp100 plasmid [115].
VaccinationofmicewithattenuatedSalmonellatyphimurium
(ST) transformed with mgp100 cDNA signiﬁcantly reduced
melanoma growth, an eﬀect which was increased by IL-2
administration [116]. In the B16/hgp100 model, vaccination
with hgp100 transformed ST was able to completely protect
more than 70% of the vaccinated mice mediated by a
strong anti-hgp100 CTL response [117]. The superiority
of xenogeneic vaccination approaches became obvious in a
study were hgp100 plasmids were applied via helium-driven
DNA-goldcomplexes leading to a tumor protection in many
of the mice which was mediated by speciﬁc CD8+ T cells
with the typical side eﬀect of autoimmune depigmentation
[118]. A comparison of hgp100 and mgp100 full-length
DNAandminigenes revealedthatonlythehumanconstructs
were able to induce a CD8+ dependent tumor protective
immunity further strengthening the xenogeneic vaccination
concept [119]. Tumor formation was completely prevented
in more than 30% of the treated C57BL/6 mice when a
hgp100 plasmid was used together with synthetic peptides
of putative CTL epitopes, an eﬀect which was not observed
if plasmid or peptides were used alone [120]. The used
study design also demonstrated a therapeutic eﬀect of the
combinatorial setting and a dependency on CD4+ and
CD8+ T cells for melanoma protection. Codelivery of IL-12
DNA by direct injection into tumors was able to further
increase the antitumorale eﬀect induced by hgp100 DNA
vaccination [121]. An autologous gp100 plasmid was able to
break self-tolerance when a diﬀerent mice model was used,
showing that diﬀerences in genetic backgrounds are critical
parameters for success of DNA vaccination [122]. DBA/2
micewerechallengedwitheithermgp100positiveornegative
syngeneic M3 melanoma cells leading to an mgp100-speciﬁc
T-cell-mediated immune response and a protection against
melanoma growth only if the mgp100 expressing cells were
used.
Similar results were obtained using TRP-1/gp75 DNA
vaccines in the B16 model in several syngeneic and xenoge-
neic settings. Murine TRP-1 (mTRP-1) expressing plasmids
were not able to break self-tolerance against mTRP-1 in
contrast to the human homologue which induced immu-
nity against mTRP-1 and subsequent tumor protection
and eradication [123]. Rejection of a lethal challenge with
B16 melanoma cells was achieved with mTRP-1 encoded
by a recombinant vaccinia virus again emphasizing that
the adjuvanticity of the delivery system is important to
break self-tolerance [124]. Boosting of DNA vaccination by
application of monoclonal antibodies is another strategy
used with a hTRP-1 DNA vaccine [125]. Lung metastases
induced by B16 were signiﬁcantly decreased if hTRP-1
DNA was used with TA99, an antibody targeting TRP-1,
as y n e r g i s t i ce ﬀect which was not seen with vaccine or
antibody alone. The TA99 antibody seemed tobe responsible
for the recruitment of TRP-1-speciﬁc CD8+ T cells to the
tumor and subsequent tumor inﬁltration.
Also DNA vaccination using TRP-2 as a target revealed
that vaccination of mice with murine TRP-2 (mTRP-2)
using vaccinia virus as a delivery system was more eﬀective
than naked DNA injection [126, 127]. Again the xenogeneic
concept was more eﬀective since hTRP-2 DNAprevented the
growth of B16 cells in the skin of treated mice by activation
of CD4+ and CD8+ Tc e l l s[ 128]. Additional treatment with
hTRP-2 after surgical resection of aﬀected extremities also
reduced the reoccurrence of local disease and the number of
lungmetastases. In summary, adjuvanticity,deliverysystems,
and prime/boost schedules are important factors to consider
from preclinical models for the design of an eﬀective DNA
vaccination strategy in humans. The design of the antigen
including signals for proteasomal degradation also plays an
important role in vaccine eﬃcacy. In this regard, fusion
of mTRP-2 to ubiquitin facilitated proteasome-dependent
degradation of antigen and subsequent presentation of
epitopes to MHC-class I leading to the generation of mTRP-
2-speciﬁc CD8+ T cells. These T cells were not only capable
to protect against melanoma but also had a therapeutic
eﬀect on established melanomas [129]. Other strategies
may enhance vaccine eﬃcacy including lymphodepletion
with cyclophosphamide and antigen fusion with heat shock
proteins. The role of lymphodepletion in adoptive T cell
transfer strategies has been demonstrated [130, 131]. Similar
conceptsmayapplyforDNAvaccines. Adenoviraldeliveryof
hTRP-2 in combination with high-dose cyclophosphamide
had a synergistic eﬀect and improved the outcome of tumor-
bearing mice [132]. Also fusion antigens are an interesting
approach tofurther enhanceimmunogenicity.Fusionofheat
shock protein 70 (Hsp70) to tumor antigens led to eﬃcient
delivery of antigen to APCs thereby breaking the immune
tolerance against melanoma cells [133]. An Hsp70-mTRP-
2 DNA vaccine was orally applied by transfected attenuated
S. typhimurium strain SL3261 protecting more than half of
the treated mice from a lethal challenge with B16 melanoma
cells in a prophylactic setting and prevented or signiﬁcantly
reduced tumor growth in a therapeutic setting.
There are promising results with a xenogeneic DNA
vaccination strategy in dogs with melanoma, which raise
hope that this strategy will succeed in humans as well.
Therapy with xenogeneic tyrosinase DNA vaccines was
used in phase I trials of spontaneous advanced malig-
nant melanoma in dogs, a disease very similar to human
melanoma. Intramuscular injections with human tyrosinase
(hTyr) plasmids signiﬁcantly increased the expected survival6 Clinical and Developmental Immunology
ofthedogscomparedtomatchedhistorical controls,andone
dog with stage IV disease had a complete clinical response
[134]. In three of the nine treated dogs, tyrosinase-speciﬁc
antibodies were induced by vaccination with hTyr DNA
which partially reacted with the syngeneic canine tyrosinase,
a phenomenon which correlated with the observed clinical
response and possibly responsible for the tumor static eﬀects
and long-term survival of the dogs [135].
In summary, the human clinical trials led to promising
results like activation of melanoma antigen-speciﬁc CTLs
but have so far not resulted in signiﬁcant improvements in
outcome. Studies in small and large animals were neverthe-
less able to demonstrate eﬃcacy of DNA vaccination against
melanoma. Some critical parameters were identiﬁed includ-
ing the delivery systems, adjuvants, and antigen design. In
general, the use of xenogeneic antigens often showed better
results in the treatment of melanoma by DNA vaccination,
and the use of viral application methods and cytokines
further increased immunogenicity. The consideration of the
lessons learned from animal models for the design of DNA
vaccination strategies may lead to an eﬀective approach in
the future.
3.Neuroblastoma
Neuroblastoma (NB) is the most common extracranial
solid tumor in childhood. The prognosis is still poor, and
the development of eﬀective treatment strategies is one
of the main objectives in pediatric oncology. Despite the
development of innovative treatment strategies like passive
immunotherapy with the anti-GD2 antibody ch14.18, the
long-time survival rate especially of stage 4 tumor patients
remains poor, ranging between 35 and 40% [136, 137].
The power of immunotherapy was demonstrated in a recent
phase III trial combining ch14.18, GM-CSF, and IL-2 with
standard therapy raising the hope to signiﬁcantly increase
the long time survival rate of high-risk patients in the near
future. Patients who received the immunotherapy showed
an improved outcome compared to standard therapy with
a two-year event-free survival (EFS) of 66% and 46%,
respectively [138].
In animal models, there are several promising results
showing that DNA vaccination is able to protect mice from
a lethal challenge with neuroblastoma tumor cells. Many
results in this respect were generated using the syngeneic
NXS2 neuroblastoma mouse model. This hybrid cell line
expresses ganglioside GD2 which is highly expressed in NB
and, as an established tumor marker, is used as a target in
clinical trials of NB immunotherapy.
The NXS2 model mimics the human disease in several
aspects. It features spontaneous metastasis to bone marrow
and liver after injection of the cells in syngeneic A/J mice,
making this system an idealmodel to study DNAvaccination
[139]. One example is cyclic mimicking decapeptides of
GD2 which were successfully used for DNA vaccination
generating protection against tumor growth and a reduction
of spontaneous liver metastases [140]. Codelivery of the
cytokines IL-15 and IL-21 enhanced the induction of GD2
directed responses which increased the CD8+ Tc el lf un cti o n .
The eﬀects were NK cell as well as CD4+ and CD8+ Tc e l l
mediated indicating the involvement of innate and adaptive
immune responses [141]. A plasmid that encoded for the
secreted form of HuD was able to induce a strong and
speciﬁc anti-HuD response in a similar mouse model using
A/J mice with the Neuro2a NB cell line. Mice that were
challenged with constitutivelyHuD-expressing Neuro2acells
were protected against tumor growth after immunization
with HuD DNA vaccine but showed no signs of neurological
disease induction [142].
The neuroblastoma antigen tyrosine hydroxylase (TH)
is another promising candidate for immunotherapy of
neuroblastoma. Tyrosine hydroxylase is involved in the ﬁrst
step of catecholamine biosynthesis, a unique feature similar
to melanin biosynthesis in melanoma, involving enzymes
restricted to the tumor tissue therefore providing tumor-
associated antigens.
Prophylactic and therapeutic vaccination with murine
TH cDNA or TH minigenes was able to protect against
tumorgrowthafterdeliveringplasmidDNAbyoralgavageof
attenuatedS. thyphimuriumtothemice.Theusedexpression
vector contained a mutated ubiquitin leading to the expres-
sion of ubiquitin-DNA fusion proteins that were eﬃciently
degraded in the proteasome. T cells recognized the TH self-
antigen epitopesindicatingthattheself-tolerance against TH
c a nb eo v e r c o m ew i t ht h i sa p p r o a c h[ 143].
In subsequent studies the same mTH-based minigenes,
novel epitopes, and xenogeneic TH DNA vaccination were
eﬀective in therapeutic settings to suppress established
neuroblastoma metastases. Modiﬁcations of mTH had addi-
tional positive eﬀects. The mutated ubiquitin of the used
plasmid was crucial for the strong antitumoral eﬀect leading
to a CD8+ T cell immune response. Primary tumors
were inﬁltrated by CD8+ T cells, and TH-expressing cells
were speciﬁcally lysed in vitro. Depletion of CD8+ T cells
completelyabrogatedtheanti-NBimmuneresponseinduced
bythehTHvaccine.Rechallengeofsurviving miceresultedin
reduced primary tumor growth, indicating the induction of
a memory immune response. An important observation was
that immunization with the self-antigen TH did not lead to
autoimmunity [18, 144, 145].
In a diﬀerent study using the same mouse model, novel
natural MHC class I ligands from neuroblastoma were
characterised andusedin aDNAminigene approach.Immu-
nization of mice induced protective immunity and thus
underlines the assumption that disruption of self-tolerance
against neuroblastoma-associated epitopes is important for
an eﬀective neuroblastoma immunotherapy [146].
The inhibitor of apoptosis protein (IAP) survivin is
highly expressed in neuroblastoma and is associated with a
poorprognosis.Therefore,survivinwaschosenasatargetfor
NB DNA vaccination. A survivin DNA minigene eﬃciently
inhibited the growth of primary tumor and metastases in
the NXS2 tumor model. The used DNA minigene was as
eﬀective as a survivin full-length cDNA vaccine showing the
power of DNA minigene vaccination. Immunization with
survivin minigene was associated with an increased presence
of CD8+ T cells in the primary tumor and productionClinical and Developmental Immunology 7
of the proinﬂammatory cytokines INF-γ and TNF-α by
systemic CD8+ T cells. Depletion of CD8+ but not CD4+
cells led to a complete abrogation of the tumor immunity.
Therapeutic vaccination with the minigene was able to
eradicate neuroblastoma in more than half of the mice, and
surviving mice were protected from primary tumor growth
after rechallenge with tumor cells [147].
In summary, these preclinical studies suggest that DNA
vaccination using S. thyphimurium as a delivery system
may provide an important strategy to develop an active
immunotherapy strategy for this challenging disease.
4.ProstateCancer
Prostate cancer is the most common cancer and the fourth
leadingcauseofcancer-relateddeathinmeninthedeveloped
countries worldwide [1, 88, 148]. Standard prostate cancer
therapy in early diagnosed patients involves prostatectomy,
cryotherapy, radiotherapy, and antiandrogen therapy. These
treatments are eﬀective but bear the risk of severe side eﬀects
like incontinence and impotence [149–151]. Therefore, there
is an urgent need for novel approaches to treat this disease.
CD4+ and CD8+ T cells are detectable in prostate glands
of men with prostate cancer supporting the assumption that
prostate cancer might be a good candidate for immunother-
apy. Prostate cancer cells are usually growing rather slow,
permitting enough time to use vaccination as an approach
to overcome immunosuppressive factors [43]. Currently,
there are several clinical trials using immunotherapy against
prostate cancer targeting prostate cancer-associated anti-
gens including Prostate-Speciﬁc Antigen (PSA) [152], Six-
Transmembrane Epithelial Antigen of the Prostate (STEAP)
[153], Prostate Stem Cell Antigen (PSCA) [154], Prostate-
Speciﬁc Membrane Antigen (PSMA) [54, 155], and Prostatic
Acid Phosphatase (PAP) [156].
PSMA was one of the ﬁrst prostate cancer-associated
antigens used for DNA vaccination. Plasmid DNA and
adenoviral vectors encoding for PSMA were used to immu-
nize patients with prostate cancer in a phase I/II trial.
Costimulation of plasmid DNA with the molecule CD86
led to delayed-type hypersensibility to PSMA in half of the
patients, but additional boosting with the adenovirus was
necessary to induce immunity in all of them. However,
the success of this study is diﬃcult to interpret due to the
heterogeneity of the patients, and the concomitant hormone
therapy many of the patients received albeit local disease,
distant metastases, and PSA levelschanged positively [39].In
another study, patients were vaccinated against PSMA with
plasmid DNAandadenovirusaswell leadingto thedetection
of speciﬁc anti-PSMA antibodies in the sera of the patients
[157]. A recent clinical phase I/II demonstrated the power of
electroporation in induction of a humoral immune response
against prostate cancer. PSMA-speciﬁc DNA vaccines were
delivered by intramuscular injection or in combination
with an additional delivery by electroporation (EP). The
boosting by EP signiﬁcantly enhanced (24.5-fold increase)
the immune response during an 18-month followup period
[54].
In summary, the eﬀorts made in clinical trials using
DNA vaccination against prostate cancer are promising,
but the response rates have to be improved. Therefore,
the evaluation and characterization of DNA vaccination
strategies in preclinical models is an important venue. The
following paragraphs summarize some ofthe research in this
respect.
One approach is the use of xenogeneic vaccination
strategies. The eﬀectiveness of mouse PSMA and human
PSMA (hPSMA) DNA vaccines were tested in an animal
model indicating that only xenogeneic hPSMA was able to
induce both antibody as well as T cell responses against
t h em u r i n es e l f - a n t i g e n .T h ea n t i b o d i e si n d u c e dw e r ea b l e
to recognize the human and the murine PSMA, and it
was concluded that xenogeneic DNA is a requirement to
overcome the immunologic tolerance against the poorly
immunogenic PSMA in contrast to other studies [158].
These results were improved in a setting with immunization
of mice using xenogeneic hPSMA DNAfollowed by boosting
with hPSMA protein [17].
Further improvements can be achieved by modiﬁcations
of DNA vaccines leading to expression and proteasomal
degradation of hPSMA in combination with protein boost-
ing.This resultedinantibody formationofthecytotoxicTh1
isotypes, andthebestprotectionagainst tumorchallengewas
observed after immunization with the xenogeneic hPSMA
construct following boosting with the syngeneic construct
[159].
The use of cytokines in order to amplify subopti-
mal immune responses following Prostate-Speciﬁc Antigen
(PSA) DNA vaccination is another strategy to increase DNA
vaccine eﬃcacy. A DNA vaccine expressing PSA induced
PSA-speciﬁc CTLs when coinjected with the costimulatory
cytokines IL-2 and GM-CSF and protected the majority of
immunized mice against a lethal tumor challenge [160].
Also, the delivery system is an important factor to induce
eﬀective immunity against prostate cancer. Intradermal
immunization of mice with PSA induced strong humoral
and cellular immune responses of the Th 1 isotype indicated
by strong expression of INF-γ and IL-2 and protected
mice from challenge with PSA-expressing tumor cells [161].
Intramuscular electroporation with human PSA (hPSA)
DNA signiﬁcantly reduced tumor growth and increased the
survival ofmiceafter alethalchallengewith hPSA-expressing
TRAMP-C1 cells, a cell line developed from a prostate
tumor of a TRAMP (transgenic adenocarcinoma mouse
prostate)mouse.ProductionofhPSA-speciﬁcantibodiesand
expression of IFN-γ was observed in the immunized animals
[51]. Multiple CTL and T-helper cell epitopes of hPSMA,
mPAP, and hPSA were combined to generate a DNA vaccine
that should havea strongereﬀectagainst prostate tumorcells
than single antigen vaccines. The vaccine design was chosen
toovercometheproblemthattumorcellsoftenloseantigenic
epitopes and escape immunologic detection. Vaccination
of mice by gene gun induced a strong immune response
against applied tumor cells and increased the survival time
signiﬁcantly [162]. A systematic comparison with other
delivery systems including life-attenuated bacteria was not
reported so far.8 Clinical and Developmental Immunology
Other antigens investigated in preclinical models are the
Prostatic Acid Phosphatase (PAP) and Prostate Stem Cell
Antigen (PSCA). PAP is eﬀective in inducing proliferating
PAP-speciﬁc CD4+ and CD8+ T cells of the Th 1 isotype
and expression of IFN-γ in rats immunized with a human
PAP DNA vaccine [163, 164]. Application of a PAP DNA
vaccine to prostate cancer patients induced a PAP-speciﬁc
T cell response and showed no side eﬀects making the use
of PAP in clinical stage II trials likely [165]. Vaccination
of mice with plasmid encoding for human PSCA induced
strong PSCA-speciﬁc CD8+ T cell responses and inhibited
the growth of PSCA-positive tumors [166]. There are no
comparative studies allowing a decision about which antigen
might be the best choice.
The models used to study DNA vaccination in prostate
cancer are usually based on the TRAMP model. In TRAMP
mice, the Simian virus 40 (SV40) tumor T-antigens are
prostate-speciﬁcally expressed driving prostate neoplasia,
which results in poorly diﬀerentiated adenocarcinomas of
the prostate and metastasis in lung and pelvic lymph nodes
resembling the human disease [167, 168]. TRAMP mice
were strongly protected against tumor development when
vaccinated with PSCA-based DNA, an eﬀect supposedly
mediated by CD8+ T cells and expression of the cytokines
INF-γ,T N F - α,I L - 2 ,I L - 4 ,a n dI L - 1 5w i t h i np r o s t a t et u m o r s .
Importantly long-term protection was not accompanied by
an induction of autoimmunity [169]. From this mouse
model, TRAMP-C1 tumor cells were isolated which grow
in syngeneic C57BL/6 mice. In this model, vaccination with
PSCA DNA by intramuscular electroporation induced an
eﬀective antitumor response, and the mice were either cured
or showed a signiﬁcant increase in survival, which was
mediated by an immunity of the Th 1 type [170].
An interesting discovery was made when two thera-
peutic vaccination studies with the antigens PSCA and
STEAP in the TRAMP mouse model were compared. DNA
vaccination at an early stage of disease resulted in an
improved protection against tumor development and an
increased survival time when compared to vaccination after
the development of invasive carcinoma. Regulatory T cells
as well as the expression of immunosuppressive factors like
TGF-β and indoleamine-2,3-dioxygenase were detected in
more advanced prostate cancer making the use of DNA
vaccination at earlier stages of disease more promising [171].
In summary, DNA vaccination against prostate cancer
has demonstrated eﬀectiveness in preclinical models, and
promising immune responses were observed in early clinical
trials. Given the amount of preclinical information on
selection and design of suitable and eﬀective antigens,
a system biology approach may provide an important
venue to translate available information into an eﬀective
immunotherapy.
5.Summary
DNA vaccination is a young ﬁeld in immunotherapy of
cancer and has certainly not yet lived up to its expectations.
However, considering the fact that the development of anti-
bodies into eﬀective cancer therapeutics followed a timeline
of over a century, DNA vaccination may be considered
to be on a fast track development. Preclinical data are
very promising and signiﬁcant immune responses can be
demonstrated inseveralclinicaltrials especially intheﬁeld of
melanoma DNA vaccination. The high versatility, the ease of
production, and the stability of DNA vaccines may provide
important characteristics to further develop this approach
into eﬀective cancer therapies of the 21st century.
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